These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Therapeutic response in oral dosage forms. Morrison AB Med Serv J Can; 1967 Mar; 23(3):349-59. PubMed ID: 6056377 [No Abstract] [Full Text] [Related]
3. Drug formulation and biologic availability. Poole JW Semin Drug Treat; 1971 Sep; 1(2):148-76. PubMed ID: 5153883 [No Abstract] [Full Text] [Related]
4. [Study of the conditions of absorption of determined drugs in various pharmaceutical oral forms]. Cardini C; Stacchini A Boll Chim Farm; 1973 Feb; 112(2):104-9. PubMed ID: 4719965 [No Abstract] [Full Text] [Related]
6. In vitro kinetics of drug release from oral dosage forms, lyophilized and conventional rectal suppositories. Bhavnagri VP; Speiser P Pharm Acta Helv; 1976; 51(1):10-8. PubMed ID: 951423 [No Abstract] [Full Text] [Related]
7. [Active ingredient release from solid drug forms--test methods, evaluation, influencing parameters]. Knop K Pharm Unserer Zeit; 1999 Nov; 28(6):301-8. PubMed ID: 10614132 [No Abstract] [Full Text] [Related]
8. Plasma concentrations after oral administration of different pharmaceutical preparations of clomethiazole. Fischler M; Frisch EP; Ortengren B Acta Pharm Suec; 1973 Dec; 10(6):483-92. PubMed ID: 4773115 [No Abstract] [Full Text] [Related]
9. [Dosage form and resorption]. Thoma K Internist (Berl); 1977 Dec; 18(12):617-27. PubMed ID: 340409 [No Abstract] [Full Text] [Related]
10. Pharmaceutical controls for drug availability. Cook D Med Serv J Can; 1967 Mar; 23(3):323-36. PubMed ID: 6056376 [No Abstract] [Full Text] [Related]
11. Dry blending process scale-up for a very low dose drug candidate. Wu LS; Pang J; Chen JG; Hussain MA AAPS PharmSciTech; 2000 Aug; 1(3):E-TN2. PubMed ID: 14727902 [No Abstract] [Full Text] [Related]
12. [Drugs for children--when temporary solutions become routine]. Kalikstad B; Westergren T Tidsskr Nor Laegeforen; 2006 Mar; 126(7):930-2. PubMed ID: 16554887 [No Abstract] [Full Text] [Related]
13. The presence of microorganisms in some common excipients used in tablet formulation. Obuekwe IF; Eichie F Acta Pol Pharm; 2006; 63(2):121-5. PubMed ID: 17514875 [TBL] [Abstract][Full Text] [Related]
14. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Zhang GG; Law D; Schmitt EA; Qiu Y Adv Drug Deliv Rev; 2004 Feb; 56(3):371-90. PubMed ID: 14962587 [TBL] [Abstract][Full Text] [Related]
15. [Card system permitting rapid identification or different solid dosage forms (tablets, chachets, pills, gelules, capsules)]. Larcan A; Bertrand JM; Lorentz JF; Valantin P; Maury G Presse Med (1893); 1971 Oct; 79(42):1853-6. PubMed ID: 5119042 [No Abstract] [Full Text] [Related]
16. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories. Jimenez FA Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711 [No Abstract] [Full Text] [Related]
17. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products. Glass BD; Haywood A J Pharm Pharm Sci; 2006; 9(3):398-426. PubMed ID: 17207422 [TBL] [Abstract][Full Text] [Related]